Micrograph showing a prostate cancer with perineural invasion. Credit: Nephron.

The Janssen Pharmaceutical Companies of Johnson & Johnson has reported that the Phase III ACIS study of Erleada and Zytiga combination in patients with metastatic castration-resistant prostate cancer (mCRPC) met the primary endpoint.

The study met the endpoint of radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve mCRPC receiving androgen deprivation therapy (ADT).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Erleada is an AR inhibitor, while Zytiga (abiraterone acetate) in combination with prednisone is indicated for treating patients with mCRPC.

The randomised, double-blind, placebo-controlled, multi-centre clinical study analysed the efficacy and safety of Erleada and Zytiga plus prednisone versus placebo and Zytiga plus prednisone in 982 patients with chemotherapy-naïve mCRPC disease who received ADT.

In the trial, the subjects randomly received either Erleada and Zytiga plus prednisone (combination arm), or placebo and Zytiga plus prednisone (control arm).

The study’s primary endpoint was rPFS while secondary endpoints included Overall Survival (OS), time to chronic opioid use, time to initiation of cytotoxic chemotherapy and time to pain progression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary efficacy analysis showed median rPFS was increased by six months in patients in the combination arm versus control arm.

An updated analysis conducted at a median follow-up of 54.8 months showed a 30% reduction in the risk of radiographic progression or death in the combination arm versus the control.

Furthermore, no statistically significant difference in OS, time to initiation of cytotoxic chemotherapy, chronic opioid use, and pain progression were observed between the treatment arms.

Janssen Research & Development Oncology, Late Development and Global Medical Affairs vice-president Craig Tendler said: “The ACIS results demonstrate the potential role of combination therapy in patients with mCRPC and underscore the continuing unmet medical need in this prostate cancer population, particularly for those patients with low AR activity tumours.

“In our commitment to advance the science and treatment of prostate cancer, these findings will help inform our research efforts in developing novel approaches and combinatory regimens to improve outcomes for these patients.”

Last October, Janssen Pharmaceutical reported that five-year data from the Phase III IM-UNITI trial of Stelara showed long-term remission in patients with moderate to severe Crohn’s disease (CD).